The thymidine phosphorylase inhibitor 5′-O-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 817-829

  Liekens, Sandra ^a   Bronckaers, Annelies ^a,e   Belleri, Mirella ^b   Bugatti, Antonella ^b   Sienaert, Rebecca ^a   Ribatti, Domenico ^c   Nico, Beatrice ^c   Gigante, Alba ^d   Casanova, Elena ^d   Opdenakker, Ghislain ^a   Pérez Pérez, María Jesús ^d   Balzarini, Jan ^a   Presta, Marco ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5' O TRITYLINOSINE; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; HEPARIN; LAMININ; PROTEIN KINASE B; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL; CELL GROWTH; CELL PROLIFERATION; CHORIOALLANTOIS; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL LINE; CHO CELLS; CRICETINAE; ENZYME INHIBITORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; INOSINE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE; TRANSFECTION; TRITYL COMPOUNDS;

EID: 84862748474     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0738     Document Type: Article

References (53)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6. (Pubitemid 43093958)
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86. (Pubitemid 46505878)
3. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
6. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-41. (Pubitemid 41337127)
7. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91.
8. Brower V. Antiangiogenesis research is booming, as questions and studies proliferate. J Natl Cancer Inst 2009;101:780-1.
9. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9. (Pubitemid 27098025)
10. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGFR modulating agents. Eur J Cancer 2009;45:1117-28.
11. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
12. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 2007;104:967-72. (Pubitemid 46154720)
13. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
14. Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell'Era P, et al. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. Mol Pharmacol 1999;56:204-13. (Pubitemid 29309830)
15. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003;9:553-66. (Pubitemid 36221723)
16. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007;13:2025-44. (Pubitemid 47040487)
17. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997;3:887-93. (Pubitemid 27353449)
18. Leali D, BianchiR,Bugatti A, Nicoli S,Mitola S,RagonaL, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived antiangiogenic pentapeptide. J Cell Mol Med 2010;14:2109-21.
19. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009;29:903-53.
20. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, et al. Angiogenic activity of enzymes. Nature 1994;368:198.
21. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687-90.
22. Hotchkiss KA, Ashton AW, Schwartz EL. Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha 5 beta 1 and alpha V beta 3. J Biol Chem 2003;278:19272-9. (Pubitemid 36799319)
23. Liekens S, Hernandez AI, Ribatti D, De Clercq E, Camarasa MJ, Perez-Perez MJ, et al. The nucleoside derivative 5′-O-trityl-inosine (KIN59) suppresses thymidine phosphorylase-triggered angiogenesis via a noncompetitive mechanism of action. J Biol Chem 2004;279:29598-605. (Pubitemid 38915842)
24. Liekens S, Balzarini J, Hernandez AI, De Clercq E, Priego EM, Camarasa MJ, et al. Thymidine phosphorylase is noncompetitively inhibited by 5′-O-trityl-inosine (KIN59) and related compounds. Nucleosides Nucleotides Nucleic Acids 2006;25:975-80. (Pubitemid 44651832)
25. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Perez-Perez MJ, et al. Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett 2002;510:83-8. (Pubitemid 34084888)
26. Ribatti D, Presta M. The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. J Cell Mol Med 2002;6:439-46. (Pubitemid 44133965)
27. Ribatti D, Cruz A, Nico B, Favier J, Vacca A, Corsi P, et al. In situ hybridization and immunogold localization of vascular endothelial growth factor receptor-2 on the pericytes of the chick chorioallantoic membrane. Cytokine 2002;17:262-5.
28. Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L, Presta M. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol 1995;170:39-49.
29. Casanova E, Perez-Perez MJ, Kappe CO. Microwave-assisted selective 5′-O-trityl protection of inosine derivatives. Synlett 2007;1733-5. (Pubitemid 47066301)
30. Grinspan JB, Mueller SN, Levine EM. Bovine endothelial cells transformed in vitro by benzo(a)pyrene. J Cell Physiol 1983;114:328-38. (Pubitemid 13161554)
31. Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscler Thromb Vasc Biol 2011;31:e116-27.
32. Bastaki M, Nelli EE, Dell'Era P, Rusnati M, Molinari-Tosatti MP, Parolini S, et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997;17:454-64. (Pubitemid 27133134)
33. Esko JD. Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 1991;3:805-16. (Pubitemid 121006137)
34. Gualandris A, Rusnati M, Belleri M, Nelli EE, Bastaki M, Molinari-Tosatti MP, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996;7:147-60. (Pubitemid 26049823)
35. Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001;276:37900-8.
36. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob Agents Chemother 2007;51:2337-45. (Pubitemid 47047308)
37. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006;1:85-91.
38. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8. (Pubitemid 351818697)
39. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97:1093-107.
40. Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol 2010;10:712-23.
41. Hallmann R, Horn N, Selg M, Wendler O, Pausch F, Sorokin LM. Expression and function of laminins in the embryonic and mature vasculature. Physiol Rev 2005;85:979-1000. (Pubitemid 40885221)
42. Ribatti D, Nico B, Vacca A, Iurlaro M, Roncali L. Temporal expression of the matrix metalloproteinase MMP-2 correlates with fibronectin immunoreactivity during the development of the vascular systemin the chick embryo chorioallantoic membrane. J Anat 1999;195:39-44. (Pubitemid 29378193)
43. Hahn-Dantona EA, Aimes RT, Quigley JP. The isolation, characterization, and molecular cloning of a 75-kDa gelatinase B-like enzyme, a member of the matrix metalloproteinase (MMP) family. An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical properties. J Biol Chem 2000;275:40827-38. (Pubitemid 32054903)
44. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res 2001;61:5057-64. (Pubitemid 32681535)
45. El Omari K, Bronckaers A, Liekens S, Perez-Perez MJ, Balzarini J, Stammers DK. Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design. Biochem J 2006;399:199-204. (Pubitemid 44570281)
46. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.
47. Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9. (Pubitemid 38879843)
48. Eble JA, Niland S. The extracellular matrix of blood vessels. Curr Pharm Des 2009;15:1385-400.
49. Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 2009;20:225-34.
50. Sola F, Gualandris A, Belleri M, Giuliani R, Coltrini D, Bastaki M, et al. Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. Angiogenesis 1997;1:102-16. (Pubitemid 127505705)
51. Garcia-Aparicio C, Bonache MC, De Meester I, San Felix A, Balzarini J, Camarasa MJ, et al. Design and discovery of a novel dipeptidylpeptidase IV (CD26)-based prodrug approach. J Med Chem 2006;49:5339-51. (Pubitemid 44260228)
52. Diez-Torrubia A, Balzarini J, Andrei G, Snoeck R, De Meester I, Camarasa MJ, et al. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. J Med Chem 2011;54:1927-42.
53. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.